-+ 0.00%
-+ 0.00%
-+ 0.00%

Rapport Therapeutics’ RAP-219 meets primary endpoint in Phase 2 bipolar mania trial

PUBT·10/20/2026 10:01:15
Listen to the news
Rapport Therapeutics’ RAP-219 meets primary endpoint in Phase 2 bipolar mania trial
  • Rapport Therapeutics announced positive Phase 2 results for RAP-219 in acute bipolar mania, meeting primary and secondary endpoints.
  • Treatment significantly improved manic symptoms versus placebo; all treatment-emergent adverse events were mild or moderate, with no serious adverse events.
  • An FDA meeting is planned for the first quarter of 2027; two Phase 3 trials are expected in the second half.
  • Additional Phase 2 results, including post-treatment safety data, will be presented at a future medical meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200600PRIMZONEFULLFEED9849210) on October 20, 2026, and is solely responsible for the information contained therein.